September 19, 2016

Both the Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization issues statements in support of the letter.

September 13, 2016
The partnership between KloudScript and Illinois independent Doc’s Pharmacy allows for patient access to specialty pharmacy treatments at retail as an alternative to mail-order specialty pharmacies. 
 
September 12, 2016

“We are excited to welcome Excelera members into NASP and important conversations around appropriate access to specialty medications and related services,” NASP membership committee chair Mike Agostino said

September 12, 2016

According to the report, some 311 medicines and vaccines for autoimmune diseases are either in clinical trials or awaiting Food and Drug Administration approval. 

September 8, 2016

"We think Kroger is going to be a winner in the health and wellness market, and we are excited to see what they build from this point forward," commented Casey Lynch, Altamont managing director.

September 7, 2016

The company is encouraging people to share their stories about experiences with cancer — either their personal experience or that of someone they know — using the hashtag #CancerTaughtMe. 

September 7, 2016

Pharmacy technology company ScriptPro is positioning itself as a provider of solutions that will ease common pain points that come with increased script volume and the influx of paperwork from clinical services with two forthcoming innovations that address pharmacy documentation needs and the will-call process.

September 6, 2016

The acquisition saw Allergan pay RetroSense Therapeutics a $60 million upfront payment, with the promise of potential regulatory and commercialization milestone payments for the company’s lead development program, RST-001 — a potential therapy for retinitis pigmentosa. 

August 30, 2016

Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R&D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the formulary, The National Law Review suggested. (The National Law Review)

August 22, 2016

The app allows hemophilia patients to record bleeding episodes and treatment while facilitating easy information sharing with their caregivers, physicians, pharmacists and nurses. 

August 22, 2016

Pfizer's proposed acquisition of biopharmaceutical company Medivation is aimed at making them a leader in the oncology space while working to bring two of Medivation's most promising late-stage assets to patients. 

August 18, 2016
 The acquisition raises the number of Genoa pharmacies in Michigan to 24, with more than 325 nationally, most of which are located onsite at community mental health centers.
August 18, 2016
The New Jersey location will consolidate the operations for its specialty brands groups, and the company is continuing its investment in the St. Louis, Mo. area, including construction on its manufacturing facility there. 
August 18, 2016

Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. 

August 16, 2016

The New York Times is reporting that the market for osteoporosis drugs might be getting a shakeup soon, as a competitor to Forteo, Eli Lilly & Co.'s osteoporosis treatment, completes a large clinical trial. The new drug uses a hormone that can build bone growth, and its maker, Radius, has an application pending before the Food and Drug Administration that the report says is expected to be approved. (New York Times)

August 15, 2016

Zinbryta is generally reserved for patients with inadequate responses to two or more multiple sclerosis therapies. 

August 10, 2016

Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015.

August 10, 2016

CareTrend allows users to manage their entire workflow operations from a single dashboard that can track output and identify delays while tracking employee productivity in real time.

August 4, 2016

USA Today is reporting that CVS Health has announced plans to remove two biologic drugs, Neupogen and Lantus, from its pharmacy benefits manager (PBM) formulary in 2017 and replace them with biosimilars of the drugs, substituting Zarxio for Neupogen and Basaglar for Lantus. Biosimilars cost about 15% to 30% less than the original biologics. CVS’s EVP and chief medical officer Troyen Brennan told USA Today that the biologics were reviewed by panels of experts “to make sure they are considered equivalent. (USA Today)

August 3, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy spending, telehealth, generics and technology, in this multi-page report.

August 2, 2016

Giant Eagle Specialty Pharmacy is dedicated to providing both choice and convenience in addition to offering patients personal support as they manage complex medical conditions, the Western Pennsylvanian retailer said.

August 2, 2016

For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.

August 2, 2016

Among the biosimilars researchers focused on was Inflectra, which was developed by Pfizer’s Hospira as a biosimilar to Janssen Biotech’s Remicade. 

August 1, 2016

The drug can now be used to treat lower limb spasticity in pediatric patients ages 2 years and older.